A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Merus B.V.
Merus B.V.
ALX Oncology Inc.
Varian, a Siemens Healthineers Company
Aktis Oncology, Inc.
Seagen Inc.
Compass Therapeutics
Eli Lilly and Company
BioNTech SE
Mucosa Innovations, S.L.
Boehringer Ingelheim
Astellas Pharma Inc
GlaxoSmithKline
USWM, LLC (dba US WorldMeds)
Seagen Inc.
Pfizer
PDS Biotechnology Corp.
Turning Point Therapeutics, Inc.
Conjupro Biotherapeutics, Inc.
Pfizer
Inhibrx Biosciences, Inc
AstraZeneca
Incyte Corporation